Published in Medicine and Law Weekly, June 9th, 2006
The needle will be attached to Bioheart's SR-200 MyoCath needle injection catheter system, which is capable of delivering biological solutions to the heart.
The agreement provides Bioheart, Inc., with the worldwide exclusive rights to four issued U.S. patents and corresponding foreign filings that cover the needle and its methods of use in the field of delivering therapeutic compositions to the heart. The needle has a closed tip...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.